Skip to main content

Table 4 Dosimetric comparisons between adaptive and phantom plans (n = 40)

From: Which nasopharyngeal cancer patients need adaptive radiotherapy?

Factors/plans (n) D98 of PTV-1 (Gy; mean ± SD) p-value Dmean of Parotid-1 (Gy; mean ± SD) p-value
BW < 60 kg   0.053   0.049
 ART(11) 15.0 ± 1.0   6.3 ± 2.4  
 Phantom(11) 13.0 ± 3.6   7.3 ± 2.9  
BW > 60 kg   0.000   0.040
 ART(29) 15.5 ± 1.8   4.8 ± 0.9  
 Phantom(29) 12.1 ± 3.8   5.3 ± 1.3  
BMI < 21.5   0.119   0.060
 ART(11) 15.1 ± 0.9   5.9 ± 2.4  
 Phantom(11) 13.7 ± 3.2   7.5 ± 3.1  
BMI > 21.5   0.000   0.034
 ART(29) 15.4 ± 1.8   4.9 ± 1.1  
 Phantom(29) 11.8 ± 3.8   5.4 ± 1.7  
BW loss < 2.8 kg   0.051   0.079
 ART(10) 15.2 ± 1.4   5.1 ± 1.2  
 Phantom(10) 12.6 ± 3.6   5.4 ± 1.6  
BW loss > 2.8 kg   0.000   0.020
 ART(30) 15.4 ± 1.7   5.5 ± 2.3  
 Phantom(30) 12.5 ± 3.2   7.1 ± 3.4  
Neo-adjuvant C/T   0.105   0.081
 ART(9) 14.9 ± 1.9   5.9 ± 2.6  
 Phantom(9) 12.5 ± 4.2   6.5 ± 3.3  
CCRT   0.000   0.015
 ART(31) 15.5 ± 1.5   4.9 ± 1.1  
 Phantom(31) 12.2 ± 3.6   5.7 ± 1.9  
Stage II†   0.069   0.671
 ART(6) 13.3 ± 1.7   4.3 ± 0.9  
 Phantom(6) 11.3 ± 2.6   4.1 ± 1.1  
Stage III/IV†   0.000   0.002
 ART(34) 15.7 ± 1.3   5.3 ± 1.6  
 Phantom(34) 12.5 ± 3.9   6.2 ± 2.3  
  1. †According to the AJCC Cancer Staging Manual, 7th Edition
  2. Abbreviations: PTV-1 planning target volume of CTV-1, D98 dose to 98% of the target volume, Dmean mean dose, BW body weight, ART adaptive radiotherapy, BMI body mass index, C/T chemotherapy, CCRT concurrent chemoradiotherapy, parotid-1 ipsilateral parotid gland